Terns Pharmaceuticals Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Amy Burroughs

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.9yrs

Jüngste Management Updates

Recent updates

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Oct 21

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 25

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 10

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Aug 18

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

May 03

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Jan 12

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Sep 29

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Jun 06

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Feb 21

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03

Terns Pharmaceuticals: The Easy Money Has Been Made

Sep 20

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Aug 08

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Jun 14

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Mar 16

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Nov 24

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Aug 24

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Jun 14

Geschäftsführer

Amy Burroughs (54 yo)

less than a year

Amtszeit

Ms. Amy L. Burroughs, M.B.A., serves as CEO & Director at Terns Pharmaceuticals, Inc. from February 07, 2024. She serves as Independent Director of Tenaya Therapeutics, Inc. since December 2022. She had be...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mark Vignola	CFO & Treasurer	4.3yrs	US$3.14m	0.027% $ 129.9k
Amy Burroughs	CEO & Director	less than a year	keine Daten	keine Daten
Elona Kogan	Chief Legal Officer	less than a year	keine Daten	keine Daten
Jeffrey Jasper	Senior Vice President of Research	2.8yrs	keine Daten	keine Daten
Emil Kuriakose	Chief Medical Officer	1.5yrs	keine Daten	keine Daten
Melita Jung	Chief Business Officer	less than a year	keine Daten	keine Daten
Scott Harris	Chief Development Officer	less than a year	keine Daten	keine Daten
Debra Sieminski	Senior Vice President of Medical Affairs	less than a year	keine Daten	keine Daten
David Strauss	VP of Finance & Controller	less than a year	keine Daten	keine Daten

0.8yrs

Durchschnittliche Betriebszugehörigkeit

46.5yo

Durchschnittliches Alter

Erfahrenes Management: TERNDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Amy Burroughs	CEO & Director	less than a year	keine Daten	keine Daten
Carl Gordon	Independent Director	6.1yrs	US$298.99k	0% $ 0
Jeffrey Kindler	Independent Director	3.9yrs	US$304.99k	0% $ 0
Heather Turner	Director	no data	keine Daten	keine Daten
Hongbo Lu	Independent Director	4.6yrs	US$299.99k	0.56% $ 2.7m
Joe Shih	Member of Scientific Advisor	no data	keine Daten	keine Daten
David Fellows	Independent Chairman	3.9yrs	US$340.15k	0% $ 0
Stephen A. Harrison	Member of Scientific Advisor	no data	keine Daten	keine Daten
Juan Lopez-Telavera	Member of Scientific Advisor	no data	keine Daten	keine Daten
Radhika Tripuraneni	Independent Director	2.3yrs	US$303.06k	0% $ 0
Michael Charlton	Member of Scientific Advisor	no data	keine Daten	keine Daten
Jill Quigley	Independent Director	3.9yrs	US$480.49k	0.018% $ 84.0k

3.9yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrener Vorstand: TERNDie Vorstandsmitglieder gelten als erfahren (3.9 Jahre durchschnittliche Amtszeit).

Terns Pharmaceuticals Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Terns Pharmaceuticals, Inc. Announces Board Changes

Independent Director recently bought US$5.0m worth of stock

Independent Director exercised options and sold US$141k worth of stock

Terns Pharmaceuticals, Inc. Announces Transition of Mark Vignola as Chief Financial Officer, Effective Until the End of January 2025

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2024

Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer

Recent updates

Terns Pharmaceuticals, Inc. Announces Board Changes

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Price target increased by 9.5% to US$18.07

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Independent Director recently bought US$5.0m worth of stock

Independent Director exercised options and sold US$141k worth of stock

Terns Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150.149762 million.

Terns Pharmaceuticals, Inc. Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Price target increased by 16% to US$16.50

Terns Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Terns Pharmaceuticals, Inc. Announces Transition of Mark Vignola as Chief Financial Officer, Effective Until the End of January 2025

Terns Pharmaceuticals, Inc. Presents New Preclinical Data Supporting TERN-501 in Combination with A GLP-1R Agonist for Obesity

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2024

Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer

New major risk - Revenue and earnings growth

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.9% to US$13.93

Price target decreased by 7.4% to US$14.29

New minor risk - Share price stability

Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

New major risk - Revenue and earnings growth

Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH

Terns Pharmaceuticals, Inc. Announces Leadership Transition

Terns Pharmaceuticals, Inc. Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased by 8.8% to US$16.14

Price target increased by 7.5% to US$14.83

Price target increased by 9.5% to US$13.80

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased by 33% to US$11.50

Price target increased to US$8.67

Price target increased to US$6.67

High number of new and inexperienced directors

Terns Pharmaceuticals, Inc. Highlights Results from Phase 1 Clinical Trial of Tern-501 At AASLD The Liver Meeting® 2022

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased to US$6.67

Terns Pharmaceuticals: The Easy Money Has Been Made

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Terns Pharmaceuticals, Inc. Announces Appointment of Radhika Tripuraneni to Board of Directors

Terns Pharmaceuticals, Inc.(NasdaqGS:TERN) dropped from Russell 2500 Value Index

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress 2022

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

No longer forecast to breakeven

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Forecast to breakeven in 2024

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Co-Founder & Executive Officer notifies of intention to sell stock

Terns Pharmaceuticals, Inc. Completes Part 1 Enrollment of Aviation Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

Terns Pharmaceuticals, Inc. Reports Positive Top-Line Results from Phase 2a Lift Study of FXR Agonist TERN-101 in Patients with NASH

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Terns Pharmaceuticals, Inc. has completed an IPO in the amount of $127.5 million.

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter